| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.33 | 0.07 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.2 | 0.6 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.006 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.17 | 0.2 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.16 | 0.4 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.15 | 0.03 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.08 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |